Please assess the completion status of the following clinical trial:

Trial Title: Mesenchymal Stem Cells to Treat Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 20 ≤ age ≤ 65 years;~2. Duration of type 2 diabetes ≤20 years;~3. 24.0 kg/m2 ≤ BMI ≤40.0 kg/m2;~4. Stable exogenous insulin dose between 0.5-1.0 U/Kg/Day with or without oral hypoglycemic agents (Dipeptidyl peptidase-4 (DPP-4) inhibitor, Glucagon like peptide 1 receptor (GLP-1R) agonist and Sodium-glucose co-transporter 2 (SGLT-2) inhibitor excluded) for at least 3 months;~5. 7.0% ≤ HbA1c ≤ 12.0%;~6. Fasting C-peptide ≥ 1ng/ml;~7. Willingness to participate in the trial.~Exclusion Criteria:~1. Patients with ketonuria, tumor, serum creatinine level more than 175μmol/L, myocardial infarction in the previous year, current angina or heart failure, more than one major vascular event, retinopathy requiring laser treatment, malignant hypertension, uncorrected endocrine disorder, occupations precluding insulin therapy;~2. Severe concurrent illness limiting life expectancy, inadequate understanding of the study protocol, drug abuse, pregnant willing and allergic constitution.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Umbilical cord mesenchymal stem cells (Type: EXPERIMENTAL): Patients receive Umbilical cord mesenchymal stem cells intravenous infusion for three times with an interval of 4 weeks in the absence of disease progression or unacceptable toxicity
- Controlled suspension liquid (Type: EXPERIMENTAL): Patients receive Controlled suspension liquid

Based on this trial design, predict the completion outcome and termination type (if applicable).